TOPLINE: Inotuzumab ozogamicin (IO), an anti‐CD22 antibody conjugated with calicheamicin, was well tolerated and demonstrated an overall response rate of 74% in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) in a real-world study. METHODOLOGY: Researchers conducted a multicentre retrospective cohort study involving 73 adult patients (median age at IO initiation...
.png)
Copyright © 2023 ghumle. All Rights Reserved
